| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 73.91% | Piper Sandler | $13 → $6 | Maintains | Overweight |
| 10/24/2023 | 189.86% | Morgan Stanley | $13 → $10 | Maintains | Equal-Weight |
| 10/16/2023 | 276.81% | Piper Sandler | $14 → $13 | Maintains | Overweight |
| 08/08/2023 | 305.8% | Piper Sandler | $15 → $14 | Maintains | Overweight |
| 08/04/2023 | 276.81% | Morgan Stanley | $14 → $13 | Maintains | Equal-Weight |
| 05/05/2023 | 305.8% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight |
| 02/16/2023 | 334.78% | Morgan Stanley | $16 → $15 | Maintains | Equal-Weight |
| 02/15/2023 | 102.9% | Credit Suisse | → $7 | Reiterates | → Underperform |
| 01/05/2023 | 334.78% | Scotiabank | → $15 | Initiates Coverage On | → Sector Outperform |
| 12/21/2022 | 305.8% | Piper Sandler | $7.5 → $14 | Upgrades | Neutral → Overweight |
| 11/07/2022 | 363.77% | Morgan Stanley | $17 → $16 | Maintains | Equal-Weight |
| 10/26/2022 | 117.39% | Piper Sandler | $12 → $7.5 | Maintains | Neutral |
| 08/25/2022 | 131.88% | Credit Suisse | → $8 | Initiates Coverage On | → Underperform |
| 08/17/2022 | 247.83% | Piper Sandler | $7.5 → $12 | Maintains | Neutral |
| 06/03/2022 | 117.39% | Piper Sandler | → $7.5 | Initiates Coverage On | → Neutral |
| 05/24/2022 | 189.86% | Goldman Sachs | $14 → $10 | Maintains | Neutral |
| 05/06/2022 | 421.74% | Morgan Stanley | $27 → $18 | Maintains | Equal-Weight |
| 02/16/2022 | 769.57% | BTIG | $35 → $30 | Maintains | Buy |
| 02/15/2022 | 682.61% | Morgan Stanley | $46 → $27 | Maintains | Equal-Weight |
| 08/06/2021 | 1407.25% | Goldman Sachs | $59 → $52 | Maintains | Neutral |
| 05/07/2021 | 1494.2% | Morgan Stanley | $60 → $55 | Maintains | Equal-Weight |
| 03/03/2021 | 1726.09% | Goldman Sachs | $74 → $63 | Downgrades | Buy → Neutral |
| 02/26/2021 | 1639.13% | Morgan Stanley | $46 → $60 | Maintains | Equal-Weight |
| 11/11/2020 | 1233.33% | Morgan Stanley | $42 → $46 | Maintains | Equal-Weight |
| 09/09/2020 | 1117.39% | Morgan Stanley | → $42 | Initiates Coverage On | → Equal-Weight |
| 05/19/2020 | 1349.28% | Guggenheim | $44 → $50 | Maintains | Buy |
| 07/23/2019 | 1233.33% | BTIG | → $46 | Initiates Coverage On | → Buy |
| 07/22/2019 | 1262.32% | Guggenheim | → $47 | Initiates Coverage On | → Buy |
| 07/22/2019 | — | William Blair | Initiates Coverage On | → Outperform | |
| 07/22/2019 | 1204.35% | B of A Securities | → $45 | Initiates Coverage On | → Buy |
| 07/22/2019 | 1204.35% | JP Morgan | → $45 | Initiates Coverage On | → Overweight |
| 07/22/2019 | 827.54% | Goldman Sachs | → $32 | Initiates Coverage On | → Neutral |
| 07/22/2019 | — | Cowen & Co. | Initiates Coverage On | → Outperform |
What is the target price for Adaptive Biotechnologies (ADPT)?
The latest price target for Adaptive Biotechnologies (NASDAQ: ADPT) was reported by Piper Sandler on November 13, 2023. The analyst firm set a price target for $6.00 expecting ADPT to rise to within 12 months (a possible 73.91% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Adaptive Biotechnologies (ADPT)?
The latest analyst rating for Adaptive Biotechnologies (NASDAQ: ADPT) was provided by Piper Sandler, and Adaptive Biotechnologies maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Adaptive Biotechnologies (ADPT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adaptive Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adaptive Biotechnologies was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
Is the Analyst Rating Adaptive Biotechnologies (ADPT) correct?
While ratings are subjective and will change, the latest Adaptive Biotechnologies (ADPT) rating was a maintained with a price target of $13.00 to $6.00. The current price Adaptive Biotechnologies (ADPT) is trading at is $3.45, which is out of the analyst's predicted range.